Tags

Type your tag names separated by a space and hit enter

Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.
Biomed Pharmacother. 2020 Aug; 128:110316.BP

Abstract

BACKGROUND

Pudilan (PDL), a four-herb prescription with the traditional function of heat-clearing and detoxifying, has been clinically used as an anti-SARS-CoV-2 infectory agent in China. PDL might also have therapeutic potentials for COVID-19 while the underlying mechanisms remain to be clarified.

METHODS

We used network pharmacology analysis and selected 68 co-targeted genes/proteins as targets of both PDL and COVID-19. These co-targeted genes/proteins were predicted by SwissDock Server for their high-precision docking simulation, and analyzed by STRING for proteins to protein interaction (PPI), pathway and GO (gene ontology) enrichment. The therapeutic effect for PDL treatment on COVID-19 was validated by the TCMATCOV (TCM Anti COVID-19) platform.

RESULTS

PDL might prevent the entrance of SARS-CoV-2 entry into cells by blocking the angiotensin-converting enzyme 2 (ACE2). It might inhibit the cytokine storm by affecting C-reactive protein (CRP), interferon-γ (IFN-γ), interleukin- 6 (IL-6), interleukin- 10 (IL-10), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), C-C motif chemokine ligand 5 (CCL5), transforming growth factor-β1 (TGFβ1), and other proteins. PDL might moderate the immune system to shorten the course of the disease, delay disease progression, and reduce the mortality rate.

CONCLUSION

PDL might have a therapeutic effect on COVID-19 through three aspects, including the moderate immune system, anti-inflammation, and anti-virus entry into cells.

Authors+Show Affiliations

Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) and Comparative Medicine Center, Peking Union Medical College (PUMC), Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, 5 Panjiayuan Nanli, Chaoyang District, Beijing 100021, PR China. Electronic address: kongqi@cnilas.org.Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) and Comparative Medicine Center, Peking Union Medical College (PUMC), Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, 5 Panjiayuan Nanli, Chaoyang District, Beijing 100021, PR China.Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) and Comparative Medicine Center, Peking Union Medical College (PUMC), Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, 5 Panjiayuan Nanli, Chaoyang District, Beijing 100021, PR China.Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) and Comparative Medicine Center, Peking Union Medical College (PUMC), Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, 5 Panjiayuan Nanli, Chaoyang District, Beijing 100021, PR China.Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) and Comparative Medicine Center, Peking Union Medical College (PUMC), Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, 5 Panjiayuan Nanli, Chaoyang District, Beijing 100021, PR China.Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) and Comparative Medicine Center, Peking Union Medical College (PUMC), Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, 5 Panjiayuan Nanli, Chaoyang District, Beijing 100021, PR China.Medical College, Qingdao University, Qingdao 266071, PR China. Electronic address: chenxiu0725@qq.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32505821

Citation

Kong, Qi, et al. "Analysis of the Molecular Mechanism of Pudilan (PDL) Treatment for COVID-19 By Network Pharmacology Tools." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 128, 2020, p. 110316.
Kong Q, Wu Y, Gu Y, et al. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. Biomed Pharmacother. 2020;128:110316.
Kong, Q., Wu, Y., Gu, Y., Lv, Q., Qi, F., Gong, S., & Chen, X. (2020). Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 128, 110316. https://doi.org/10.1016/j.biopha.2020.110316
Kong Q, et al. Analysis of the Molecular Mechanism of Pudilan (PDL) Treatment for COVID-19 By Network Pharmacology Tools. Biomed Pharmacother. 2020;128:110316. PubMed PMID: 32505821.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. AU - Kong,Qi, AU - Wu,Yue, AU - Gu,Yu, AU - Lv,Qi, AU - Qi,Feifei, AU - Gong,Shuran, AU - Chen,Xiuping, Y1 - 2020/05/30/ PY - 2020/05/01/received PY - 2020/05/21/revised PY - 2020/05/22/accepted PY - 2020/6/9/pubmed PY - 2020/7/1/medline PY - 2020/6/8/entrez KW - COVID-19 KW - Network pharmacology KW - SARS-CoV-2 infection KW - Targeted therapy KW - Traditional Chinese herbs SP - 110316 EP - 110316 JF - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JO - Biomed. Pharmacother. VL - 128 N2 - BACKGROUND: Pudilan (PDL), a four-herb prescription with the traditional function of heat-clearing and detoxifying, has been clinically used as an anti-SARS-CoV-2 infectory agent in China. PDL might also have therapeutic potentials for COVID-19 while the underlying mechanisms remain to be clarified. METHODS: We used network pharmacology analysis and selected 68 co-targeted genes/proteins as targets of both PDL and COVID-19. These co-targeted genes/proteins were predicted by SwissDock Server for their high-precision docking simulation, and analyzed by STRING for proteins to protein interaction (PPI), pathway and GO (gene ontology) enrichment. The therapeutic effect for PDL treatment on COVID-19 was validated by the TCMATCOV (TCM Anti COVID-19) platform. RESULTS: PDL might prevent the entrance of SARS-CoV-2 entry into cells by blocking the angiotensin-converting enzyme 2 (ACE2). It might inhibit the cytokine storm by affecting C-reactive protein (CRP), interferon-γ (IFN-γ), interleukin- 6 (IL-6), interleukin- 10 (IL-10), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), C-C motif chemokine ligand 5 (CCL5), transforming growth factor-β1 (TGFβ1), and other proteins. PDL might moderate the immune system to shorten the course of the disease, delay disease progression, and reduce the mortality rate. CONCLUSION: PDL might have a therapeutic effect on COVID-19 through three aspects, including the moderate immune system, anti-inflammation, and anti-virus entry into cells. SN - 1950-6007 UR - https://www.unboundmedicine.com/medline/citation/32505821/Analysis_of_the_molecular_mechanism_of_Pudilan__PDL__treatment_for_COVID_19_by_network_pharmacology_tools_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0753-3322(20)30508-4 DB - PRIME DP - Unbound Medicine ER -